Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Khurum Khan(Cancer Institute (WIA)), T.R. Jeffry Evans(Leiden University Medical Center), Elisabeth Oelmann(Nucana (United Kingdom)), David Cosgrove(Compass Oncology), Hélène Marijon(Cedars-Sinai Medical Center), Jordan Berlin(Dana-Farber Cancer Institute), Kristen K. Ciombor(The Ohio State University), Fiona G. McKissock(Nucana (United Kingdom)), Uma Mukherjee(University College London Hospitals NHS Foundation Trust), Aimery de Gramont(Institut Hospitalier Franco Britannique), Andrew L. Coveler(University of Washington), Benjamin L. Schlechter(Brigham and Women's Hospital), Stacey A. Cohen(Fred Hutch Cancer Center), Sarah P. Blagden(Churchill Hospital), Niharika B. Mettu(Duke Medical Center), Janet Graham(Beatson West of Scotland Cancer Centre), Aglaia Skolariki(MRC Clinical Trials Unit at UCL), Jeffrey D. Bloss(Nucana (United Kingdom)), Mary Linton B. Peters(Beth Israel Deaconess Medical Center)
Cited by 1
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k